Targeting the c-MET signaling pathway for cancer therapy

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Expert Opinion's
Reply to topic
Targeting the c-MET signaling pathway for cancer therapy
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Mon Jun 23, 2008 1:31 pm Reply with quote


Expert Opinion on Investigational Drugs , July 2008, Vol. 17, No. 7, Pages 997-1011.
<br/>
Background: In many human cancers, c-MET is activated via receptor overexpression, amplification, mutation and/or a ligand-dependent autocrine/paracrine loop. These biochemical and genetic abnormalities have been correlated with poor clinical outcomes and ...

Read more...

Source: Expert Opinion: Expert Opinion on Investigational Drugs: Table of Contents
Table of Contents for Expert Opinion on Investigational Drugs. List of articles from both the latest and ahead of print issues.
View user's profileSend private message
Targeting the c-MET signaling pathway for cancer therapy
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Expert Opinion's
 Reply to topic  
Forum Map
Site Map